Rate My Professor Andrew Martin

Professor Martin provides statistical leadership to clinical trial networks in various disease areas, including the design, conduct, analysis, and reporting of clinical trials. He is responsible for content development, coordination, and teaching of postgraduate units in decision analysis and controlled clinical trials at the University of Sydney, as well as courses and workshops in clinical trial concept development and statistical methods. He serves as Biostatistical Editor for Therapeutic Advances in Medical Oncology. Key publications include 'Protocol for the Lactoferrin Infant Feeding Trial (LIFT): a randomised trial' (BMJ Open, 2018), 'BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy' (BMC Cancer, 2015), 'ENZA-p trial protocol: a randomized phase II trial' (BJU International, 2021), 'Effect Sizes Hypothesized and Observed in Contemporary Phase III Cancer Clinical Trials' (JNCI Cancer Spectrum, 2018), 'Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy' (JNCI Cancer Spectrum, 2020), and 'Challenges of estimating treatment effects after a positive interim analysis' (European Journal of Cancer, 2024).